InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by COLWILL BRUCE, Chief Financial Officer. Officer active across 1 companies, notably InMed Pharmaceuticals Inc.. Cumulatively, 4 disclosures have been recorded. Total volume traded: €25k. The latest transaction was disclosed on 24 January 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
€4,7955,000 shares@ €0.95938.8% of flow
Common Stock
SEC:0001213900-22-003286·
Ideal exit: 21 Oct 2022 (T+270)
€4,7955,000 shares@ €0.9590.074% mcap19.4% of flow
Common Stock
SEC:0001213900-22-003286:0·
Ideal exit: 21 Oct 2022 (T+270)
€7,5645,000 shares@ €1.512961.2% of flow
Common Stock
SEC:0001213900-21-050521·
Ideal exit: 25 Jun 2022 (T+270)
€7,5645,000 shares@ €1.51290.12% mcap30.6% of flow
Common Stock
SEC:0001213900-21-050521:0·
Ideal exit: 25 Jun 2022 (T+270)
4 of 4 declarations
About COLWILL BRUCE
Bruce Colwill is the Chief Financial Officer of InMed Pharmaceuticals Inc. He is responsible for the financial management of the company, including budgeting, financial risk management, and regulatory compliance. Bruce plays a crucial role in the strategic direction of InMed, which focuses on developing cannabis-based therapies. His expertise in corporate finance is essential to support growth and innovation within the company.
